September 8, 2022 C-Path’s Kristen Swingle Named President Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-
September 7, 2022 Evaluating the Use of Backup Solutions for ePRO Systems has been published in Applied Clinical Trials
September 1, 2022 Drug Development for Cystic Kidney Diseases Inherited cystic diseases include a spectrum of disorders, such as autosomal dominant polycystic kidney disease (ADPKD), autosomal
September 1, 2022 C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases TUCSON, Ariz., Sept. 1, 2022 — Critical Path Institute (C-Path) today announced the launch of a pre-consortium collaboration foc
August 26, 2022 Four PKD Reports Published in CJASN C-Path and PKDOC are excited to announce that four reports summarizing Sessions 1, 2, and 3B from the 2021 PKD Regulatory Summit h
August 25, 2022 Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug Development C-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platfo
August 24, 2022 Oak Hill Bio Joins C-Path’s International Neonatal Consortium TUCSON, Ariz., Aug. 24, 2022 — Critical Path Institute (C-Path) today announced that Oak Hill Bio (Oak Hill), a clinical-stage n
August 17, 2022 View Now | Addressing the Gaps in Clinical Trial Readiness for FSHD Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common myopathies affecting anywhere between 1:8,000 to 1:20,000
August 16, 2022 Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD Autosomal dominant polycystic kidney disease (ADPKD) is a major genetic disorder affecting up to 12 million individuals worldwide
